Form 4: Neurocrine Biosciences Executive Julie Cooke Reports Stock Transactions
SEC Form 4 Filing
Chief Human Resources Officer Julie Cooke of Neurocrine Biosciences reports the vesting of restricted stock units and subsequent sale of shares under a pre-arranged trading plan.
Summary
- Julie Cooke, Chief Human Resources Officer of Neurocrine Biosciences, filed a Form 4 detailing changes in beneficial ownership.
- On February 8, 2025, 1,329 restricted stock units (RSUs) vested, converting into common stock.
- Also on February 8, 2025, 1,329 shares were acquired upon vesting of the RSUs.
- On February 10, 2025, Ms. Cooke sold 700 shares of common stock at a weighted average price of $118.275 per share.
- The sales were executed under a Rule 10b5-1 trading plan adopted on June 10, 2021.
- Following these transactions, Ms. Cooke directly owns 18,831 shares and indirectly owns 16,538 shares through the Cooke Family Trust of 2004.
Sentiment
Score: 5
Explanation: Neutral sentiment as the filing reflects routine transactions under a pre-existing trading plan, with no indication of unusual activity or concerns.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge executive sentiment and potential future stock performance.
Key Dates
| Date | Description |
|---|---|
| 06/10/2021 | Date of adoption of Rule 10b5-1 trading plan |
| 02/08/2021 | Date the Restricted Stock Unit was granted to the Reporting Person |
| 02/08/2022 | Date 1,328 shares of the RSU vested |
| 02/08/2023 | Date 1,328 shares of the RSU vested |
| 02/08/2024 | Date 1,329 shares of the RSU vested |
| 12/28/2004 | Date of Cooke Family Trust of 2004 U/A |
| 02/08/2025 | Restricted stock units vested and shares acquired |
| 02/10/2025 | Shares of common stock sold |
| 02/12/2025 | Date of Form 4 filing |
Keywords
Form 4, Beneficial Ownership, Neurocrine Biosciences, NBIX, Julie Cooke, Restricted Stock Units, Rule 10b5-1, Stock Sale, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.